此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy

2019年9月7日 更新者:Ghadeer abdelrazzak mohammed、Assiut University

Transcription Factor 7 Like 2 Gene Polymorphism and Advanced Glycation End Products as Risk Factors for Diabetic Nephropathy

  1. To study genotypic distribution of the TCF7L2 gene polymorphism in Diabetic nephropathy.
  2. To assess level of AGEs and Insulin in patients with Diabetic nephropathy.
  3. To study correlation between polymorphism of the TCF7L2 gene, AGEs, Insulin and clinical characteristics in patients with diabetic nephropathy

研究概览

地位

未知

详细说明

Diabetic nephropathy is one of microvascular complications of diabetes mellitus. DN is a multifactorial disorder that occurs in one third of patients with long standing DM. DN is one of the most serious complications that being a major contributing factor to end-stage renal disease and death in diabetic patients. The earliest clinical indication of DN is the appearance of microalbuminuria. Detection of diabetic nephropathy as early as possible, is the best chance of delaying progression to ESRD. Thus, screening for microalbuminuria is recommended annually immediately after a diagnosis of diabetes. Transcription factor 7-like 2 is a highly variable transcription factor, which is a key component of the Wnt-signaling pathway and plays a role in the regulation of insulin secretion by pancreatic beta cells and the maintenance of glucose homeostasis. TCF7L2 rs7903146 polymorphism is more associated with T2DM which mediated by decreased insulin secretion associated with defects in insulin processing, reduced effects of glucagon-like peptide-1, increased hepatic glucose production and insulin resistance. The mutant TT genotype and the T allele frequency was associated with diabetic patients who developed nephropathy. Advanced glycation end products are generated by the non-enzymatic reaction of amino groups in DNA and proteins with reducing sugars. AGEs accumulate in glomerular basement membrane. The AGEs-RAGE interaction is a causative factor for DN through activating a series of intracellular signal-cascade pathways which induce the generation of further signalling factors, such as vascular endothelial growth factor, transforming growth factor B, nuclear factor-κβ. Those signalling factors cause mesangial expansion and glomerulosclerosis.

研究类型

观察性的

注册 (预期的)

100

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

取样方法

非概率样本

研究人群

  • 60 diabetic patients: Diagnosis of DM was based on the American Diabetes Association Criteria:

    -The diabetic patients will be classified into 2 subgroups:

  • 30 Diabetic patients without any microvascular or macrovascular complications.
  • 30 Diabetic patients with pure nephropathy not having other microvascular or macrovascular complications.
  • 20 patients diagnosed as prediabetes:
  • Beside 20 Apparent healthy subjects as control group.

描述

Inclusion Criteria:

  • diabetic nephropathy
  • clinical diagnosis of prediabetes
  • Type 2 diabetic patients

Exclusion Criteria:

  • cardiovascular disease
  • diabetic neuropathy
  • diabetic retinopathy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of diabetic nephropathy
大体时间:one year

find a link between genetic polymorphism of TCF7L2 and the risk of developing nephropathy in diabetic patients.

Nephropathy is defined Albumin/creatinine ratio > 30 mg/gm creat.

one year
Number of patients with genotype TCF7L2 by PCR
大体时间:5 years

the prevalence of TCF7L2, in the diabetic patient, and compared to the values found in the general population.

the TCF7L2 genes will be evaluated by PCR-RFLP

5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2019年9月1日

初级完成 (预期的)

2020年9月1日

研究完成 (预期的)

2020年10月1日

研究注册日期

首次提交

2019年9月3日

首先提交符合 QC 标准的

2019年9月7日

首次发布 (实际的)

2019年9月10日

研究记录更新

最后更新发布 (实际的)

2019年9月10日

上次提交的符合 QC 标准的更新

2019年9月7日

最后验证

2019年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • TCF7L2 in Diabetic nephropathy

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅